[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536504":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":114,"collaborators":11,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":11,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":11,"enrollmentInfo":125,"targetDuration":11,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"CytomX Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CX-2051","EXPERIMENTAL",null,[13],"Drug: CX-2051",{"label":15,"type":10,"description":11,"interventionNames":16},"CX-2051 + bevacizumab",[13,17],"Drug: Bevacizumab",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Investigational drug",[9,15],{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Bevacizumab","IV infusion",[15],[28],"Avastin",[30],{"name":31,"affiliation":5,"role":32},"Monika Vainorius, MD","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Karen Deane","CONTACT","650-515-3185","clinicaltrials@cytomx.com",[40,54,64,74,84,94,104],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"Sarah Cannon Research Institute at HealthONE","RECRUITING","Denver","Colorado","80218","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-104.9847,39.73915,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":57,"zip":58,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":63,"contacts":11},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":49,"coordinates":60},[61,62],-71.05977,42.35843,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":67,"zip":68,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"Montefiore Medical Center","The Bronx","New York","10461",{"type":49,"coordinates":70},[71,72],-73.86641,40.84985,{"lat":72,"lon":71},{"facility":75,"status":42,"city":76,"state":77,"zip":78,"country":46,"countryCode":47,"cosmosGeoPoint":79,"geoPoint":83,"contacts":11},"Carolina BioOncology Institute, PLLC","Huntersville","North Carolina","28078",{"type":49,"coordinates":80},[81,82],-80.84285,35.41069,{"lat":82,"lon":81},{"facility":85,"status":42,"city":86,"state":87,"zip":88,"country":46,"countryCode":47,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"Sarah Cannon Research Institute, LLC","Nashville","Tennessee","37203",{"type":49,"coordinates":90},[91,92],-86.78444,36.16589,{"lat":92,"lon":91},{"facility":95,"status":42,"city":96,"state":97,"zip":98,"country":46,"countryCode":47,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"START San Antonio LLC","San Antonio","Texas","78229",{"type":49,"coordinates":100},[101,102],-98.49363,29.42412,{"lat":102,"lon":101},{"facility":105,"status":42,"city":106,"state":107,"zip":108,"country":46,"countryCode":47,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":49,"coordinates":110},[111,112],-77.30637,38.84622,{"lat":112,"lon":111},{"type":115,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100536504","phase-1-first-in-human-study-of-cx-2051-in-advanced-solid-tumors-100536504",false,"NCT06265688","First In Human Study of CX-2051 in Advanced Solid Tumors","An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1\n* Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload\n* Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1\n* Elevated baseline laboratory values\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply","ALL","18 Years",{"count":126,"type":127},160,"ESTIMATED","INTERVENTIONAL",[130],"PHASE1","The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.",[133],"Solid Tumor, Adult","2026-06-23",{"date":136,"type":137},"2026-06-25","ACTUAL",{"date":139,"type":137},"2024-04-02",{"date":141,"type":127},"2029-03-31",{"name":5,"class":6},7]